Company News

02/16/2022

TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called Lacripep, today announced that in late 2021 it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Lacripep

02/16/2022

ADIAL PHARMACEUTICALS ANNOUNCES CLOSING OF $10 MILLION FINANCING

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately $10 million of

02/16/2022

ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin

CHARLOTTESVILLE, Va., /PRNewswire/ — ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer through its innovative ZielFind drug discovery platform, today announced the first patient dosed in its Phase 1/2 clinical trial. The study will evaluate ZB131 in patients with solid tumors who are either non-responsive to or ineligible for the standard

02/16/2022

ATCC Announces Awards from DTRA that Strengthen ATCC’s Antiviral Drug Discovery and Development Portfolio for Global Health and Biodefense

Manassas, VA, ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA). The work will identify and characterize novel therapeutic approaches to viruses of global health concern. Promising therapeutic candidates will be tested for efficacy with

02/16/2022

ATCC Announces Awards from DTRA that Strengthen ATCC’s Antiviral Drug Discovery and Development Portfolio for Global Health and Biodefense

Manassas, VA, ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA). The work will identify and characterize novel therapeutic approaches to viruses of global health concern. Promising therapeutic candidates will be tested for efficacy with in

02/11/2022

Vibrent Health Rebrands its Health Research Participant Portal as “Participant Cloud” to Reflect Virtual Research Capabilities, Accessibility and Flexibility

Vibrent Health enhances and rebrands its consumer-facing digital health platform for data collection, recruitment and engagement of health research participants   Fairfax, VA., – Vibrent Health, a digital health technology startup dedicated to powering the future of precision health research, announced a rebranding of their participant-facing digital health research portal and mobile apps, formerly the